Application Note

Cytograde™ pDNA: Manufacture pDNA Without Sacrificing Quality Or Budget

By David Schmidt, Cytovance Biologics

lab flask science 450x300

Many pharmaceutical manufacturers require clarity on quality standards for the use of plasmid DNA (pDNA) as a reagent, or as the final active pharmaceutical ingredient (API). Organizations working on viral vector-based gene therapies use pDNA as an integral part of their production workflow. However, as pDNA can also be the final API in therapeutics such as DNA vaccines – and subsequently be in direct contact with patients – establishing efficient, cost-effective quality oversight is crucial to minimize risks while staying on budget.

At Cytovance, a CDMO specializing in rapid development and manufacture of large molecule APIs, many of our clients engage us to create a “GMP light” development framework that reduces overhead, while guaranteeing quality assurance. Although “GMP light” does not exist, the team at Cytovance has developed a compelling new service offering – Cytograde™ pDNA – to help our clients produce high-quality, affordable pDNA for any process and at any developmental stage. Cytovance Biologics integrates world-class processes and scalable single- or multi-use equipment to efficiently produce superior plasmids.

VIEW THE APPLICATION NOTE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: